Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2022-11-09 Interim / Quarterly Rep…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2022
2022-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2022, reporting the issuance of a press release announcing financial results for the quarter ended September 30, 2022. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K itself is a current report, not the full financial report. The document length is 3436 characters, which is relatively short and consistent with an announcement rather than a full earnings release. The key section is Item 2.02, which is for "Results of Operations and Financial Condition," typically used to announce earnings results. However, since the document is primarily an announcement of the earnings release (press release) and does not contain the financial results themselves, it fits the definition of an Earnings Release (ER) announcement. Given the short length and nature of the document, it is best classified as an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR).
2022-11-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an FDA approval event for a plasma collection facility and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (3330 characters). It is not an annual or quarterly report, nor an earnings release. The document is an announcement of a material event rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-10-31 English
Director's Dealing 2022
Director's Dealing
2022-10-05 English
Director's Dealing 2022
Director's Dealing
2022-10-05 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-10 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.